jRCT2041260087尚未招募不适用
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT) (ARGiNAUT)
未提供0 个研究点目标入组 18 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 40age old over 至 No limit（—）
- 性别
- All
入选标准
- •Age >_ 40 years
- •IPF diagnosis
- •Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
- •FVC >_ 45% predicted of normal
- •DLCO corrected for hemoglobin >_ 25% predicted of normal
排除标准
- •ILD other than IPF
- •The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
- •Acute exacerbation of IPF
- •Lower respiratory tract infection requiring treatment
- •Acute coronary syndrome/acute myocardial infarction, unstable angina +- coronary intervention with Percutaneous Coronary Interv
- •ention, or Coronary Artery Bypass Grafting
- •Heart failure
- •History of organ transplantation or is likely to receive lung transplantation
研究者
相似试验
尚未招募
不适用
Reducing Mechanical Ventilation through administration of Invimestrocel in patients with ARDS (REVIVE-ARDS)Acute Respiratory Distress Syndrome (ARDS)jRCT207326003720
招募中
不适用
JBCRG-M11 ( CAERUS trial )
(JBCRG-M11 ( CAERUS trial ))Hormone receptor-positive and HER2-low metastatic breast cancerjRCT2051260024110
尚未招募
2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
招募中
1 期
Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).2023-509776-41-00Instituto Oncologico Dr. Rosell S.L.48
尚未招募
2 期
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.NCT07487519Shanghai Henlius Biotech180